Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Protara Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
18.9
21.7
11.8
3.88
12
21.1
16.8
25
31.7
42.6
General and administrative
9.84
8.68
9.52
3.95
22.5
26.4
20.7
18.6
17.5
21.9
Operating expenses
28.7
30.4
21.4
7.83
34.4
47.5
67.1
43.6
49.2
64.5
Operating income
-28.7
-30.4
-21.4
-7.83
-34.4
-47.5
-67.1
-43.6
-49.2
-64.5
Interest expense
0.03
0
Interest income
0.5
0.24
1.11
3.19
4.17
6.38
Other non-operating income
0.18
0.4
0.64
0.26
0.47
0.24
1.11
3.19
4.56
7.11
Pre-tax income
-28.5
-30
-20.7
-15
44.6
57.4
Net income
-28.5
-30
-20.7
-7.83
-34
-47.3
-66
-40.4
-44.6
-57.4
EBITDA
-28.6
-30.2
-21.3
-7.81
-34.3
-47.4
-66.8
-43.3
-48.8
-64.2
EPS, basic
-6.91
-8.55
-4.62
-3.04
-4.70
-4.21
-5.86
-3.57
-2.17
-1.34
EPS, diluted
-6.91
-8.55
-4.62
-3.04
-4.70
-4.21
-5.86
-3.57
-2.17
-1.34
Shares, basic (weighted)
4.12
4.3
4.49
2.58
7.23
11.2
11.3
11.3
20.6
42.8
Shares, diluted (weighted)
4.12
4.3
4.49
2.58
7.23
11.2
11.3
11.3
20.6
42.8
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
36.4
21.2
19.4
0.56
169
35.7
24.1
39.6
163
49.7
Short-term investments
55.5
60.2
26
7.49
106
Other current assets
1.44
1.34
1.37
0.08
0.05
0.03
0.13
0.04
0
0.07
Total current assets
42.8
43.5
23.2
0.76
169
93.1
86.1
68.7
172
160
Property, plant and equipment
0.37
0.26
0.26
0.46
1.24
1.72
1.59
1.3
1.03
0.76
Lease right-of-use assets
1.06
7.17
6.28
5.26
4.26
3.17
Goodwill
29.5
29.5
Long-term investments
39.5
17.9
42.3
Other non-current assets
0.39
0.22
1.16
0.87
0.02
0.01
0.03
0.02
Total assets
43.5
44
23.5
1.22
203
173
113
79
181
209
Accounts payable
0.56
0.29
0.44
0.72
0.91
0.95
1.59
2.43
4.43
3.47
Accrued liabilities
4.52
8.95
2.64
2.64
1.91
2.49
3.24
2.73
5.41
6.23
Short-term debt
0
0
Total current liabilities
5.08
9.24
3.08
3.35
2.92
4.3
5.74
6.15
11
10.9
Lease liabilities
1
6.38
5.47
4.48
3.36
2.12
Total liabilities
5.08
9.24
3.08
3.35
3.91
10.7
11.2
10.6
14.3
13.1
Paid-in capital
198
203
209
10.7
246
256
263
269
412
499
Retained earnings
-160
-190
-210
-12.8
-46.8
-94
-160
-200
-245
-302
Other comprehensive income
-0.01
0.01
0
-0.21
-0.69
-0.03
0
0.09
Shareholders' equity
38.4
34.7
4.78
-2.13
199
162
102
68.3
167
196
Total equity
38.4
34.7
4.78
-2.13
199
162
102
68.3
167
196
Total liabilities and equity
43.5
44
23.5
1.22
203
173
113
79
181
209
Shares outstanding
4.13
4.4
4.77
2.63
11.2
11.2
11.3
11.4
35
53.6
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-28.5
-30
-20.7
-7.83
-34
-47.3
-66
-40.4
-44.6
-57.4
Depreciation and amortization
0.12
0.15
0.12
0.02
0.1
0.12
0.25
0.34
0.33
0.36
Stock-based compensation
3.34
3.23
3.43
0.42
9.75
10.4
6.69
6.09
4.13
3.83
Deferred income tax
-8.65
-4.62
-9.02
-13.8
-19.8
-11
Change in payables
1.07
4.16
-6.16
0.37
0.2
0.04
0.63
0.85
1.38
-0.87
Cash from operations
-23.7
-22.4
-23.2
-5.01
-23.4
-34.5
-26.5
-37.6
-35.8
-56.4
Capital expenditures
-0.27
-0.04
-0.12
-0.48
-0.88
-0.6
-0.12
-0.05
-0.06
-0.09
Acquisitions
3.72
Purchases of investments
-125
-43.6
-12.2
-29.4
-205
Sales and maturities of investments
59.9
16.9
32
2.5
58.6
65.3
48.6
65.2
Cash from investing
19.9
-16.1
18.4
-0.48
2.84
-98.2
15
53.1
19.2
-139
Stock issued
0.2
0.11
73.6
0.14
0.02
Share buybacks
-0.23
-0.09
-0.09
Cash from financing
0.21
23
2.99
0.5
189
-0.23
-0.09
-0.09
140
82.7
Exchange rate effect
-0.08
0.18
Net change in cash
-3.64
-15.2
-1.8
-13.2
169
-133
-11.6
15.5
123
-113
Free cash flow
-24
-22.4
-23.4
-5.49
-24.3
-35.1
-26.6
-37.6
-35.9
-56.5
Interest paid
0.03
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.28 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-43.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-39.8%
Net income / average total assets.
Return on invested capital (ROIC)
-42.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
17.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
24.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-0.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
15.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
22.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
0.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
108.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
56.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
42.7%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
11.0x
Current assets / current liabilities.
Quick ratio
10.7x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
10.7x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$1.08
Cash from operations / diluted weighted shares.
Book value per share
$2.73
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.20x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.20x
Market cap / tangible book value, when positive.
Earnings yield
-36.1%
Net income / market cap (the inverse of P/E).
Was Protara Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $57.4M.
How much free cash flow did Protara Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $56.4M minus capital expenditures of $94.0K left free cash flow of -$56.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.